Vaccines

25 Feb 2021 AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19
25 Feb 2021 Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
25 Feb 2021 Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study
24 Feb 2021 U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)
24 Feb 2021 Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
23 Feb 2021 INOVIO announces first subject dosed in Phase 1B clinical trial for its DNA vaccine against Lassa fever, INO-4500, in West Africa
22 Feb 2021 Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
22 Feb 2021 Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
22 Feb 2021 Amyris Announces Positive Pre-Clinical Results For COVID-19 RNA Vaccine Platform With Advantaged Manufacturing, Storage And Distribution Characteristics
22 Feb 2021 Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
20 Feb 2021 Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
20 Feb 2021 Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine
19 Feb 2021 Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
19 Feb 2021 Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women
18 Feb 2021 Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
17 Feb 2021 Altimmune Announces FDA Clearance of AdCOVID™ IND Application
17 Feb 2021 Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
16 Feb 2021 AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
12 Feb 2021 ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
12 Feb 2021 CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV
10 Feb 2021 AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
08 Feb 2021 Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
08 Feb 2021 COVAXX’s COVID-19 Vaccine, UB-612, Induced Neutralizing Antibodies in 100% of Participants During Phase 1 Clinical Trial
06 Feb 2021 Science Advances: Elicio Therapeutics’ SARS-CoV-2 Vaccine Demonstrates T Cell Responses >25 Fold Higher Than Benchmark Vaccines
06 Feb 2021 Sinovac Announces Phase III Results of Its COVID-19 Vaccine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top